Evidence map›Paper›PMID 24122122›Full record

Trial reportCancer2014

Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma.

Kaoru Tsuchiya, Yasuhiro Asahina, Shuya Matsuda, Masaru Muraoka, Toru Nakata, Yuichiro Suzuki, Nobuharu Tamaki, Yutaka Yasui, Shoko Suzuki, Takanori Hosokawa and 9 more

Open access · hybridAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 2 pooled it
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 2 syntheses or guidelines pooled it, 67 citations in OpenAlex.

  1. Pooled it
  2. Prognostic Value of VEGF in Hepatocellular Carcinoma Patients Treated with Sorafenib: A Meta-Analysis.Medical science monitor : international medical journal of experimental and clinical research · 2015
    Pooled it
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Observational
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review article: systemic treatment of hepatocellular carcinoma.Alimentary pharmacology & therapeutics · 2018
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 3 institutions in 1 country.

Kaoru TsuchiyaDepartment of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan.
Yasuhiro Asahina
Shuya Matsuda
Masaru Muraoka
Toru Nakata
Yuichiro Suzuki
Nobuharu Tamaki
Yutaka Yasui
Shoko Suzuki
Takanori Hosokawa
Takashi Nishimura
Ken Ueda
Teiji Kuzuya
Hiroyuki Nakanishi
Jun Itakura
Yuka Takahashi
Masayuki Kurosaki
Nobuyuki Enomoto
Namiki Izumi
Musashino Red Cross Hospital · JPTokyo Medical and Dental University · JPUniversity of Yamanashi · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundA new predictive biomarker for determining prognosis in patients with hepatocellular carcinoma (HCC) who receive sorafenib is required, because achieving a reduction in tumor size with sorafenib is rare, even in patients who have a favorable prognosis. Vascular endothelial growth factor (VEGF) receptor is a sorafenib target. In the current study, the authors examined changes in plasma VEGF concentrations during sorafenib treatment and determined the clinical significance of VEGF as a prognostic indicator in patients with HCC.

methodsPlasma VEGF concentrations were serially measured in 63 patients with advanced HCC before and during sorafenib treatment. A plasma VEGF concentration that decreased >5% from the pretreatment level at 8 weeks was defined as a "VEGF decrease." An objective tumor response was determined using modified Response Evaluation Criteria in Solid Tumors 1 month after the initiation of therapy and every 3 months thereafter.

resultsPatients who had a VEGF decrease at week 8 (n=14) had a longer median survival than those who did not have a VEGF decrease (n=49; 30.9 months vs 14.4 months; P=.038). All patients who had a VEGF decrease survived for >6 months, and the patients who had both a VEGF decrease and an α-fetoprotein response (n=6) survived during the observation period (median, 19.7 months; range, 6.5-31.0 months). In univariate analyses, a VEGF decrease, radiologic findings classified as progressive disease, and major vascular invasion were associated significantly with 1-year survival; and, in multivariate analysis, a VEGF decrease was identified as an independent factor associated significantly with survival.

conclusionsA plasma VEGF concentration decrease at 8 weeks after starting sorafenib treatment may predict favorable overall survival in patients with advanced HCC.

Indexed as

AdultAgedAged, 80 and overalpha-FetoproteinsBiomarkers, TumorCarcinoma, HepatocellularFemaleHumansLiver NeoplasmsMaleMiddle AgedMultivariate AnalysisNiacinamidePhenylurea CompoundsPredictive Value of TestsPrognosisAFP protein, humanalpha-FetoproteinsBiomarkers, TumorNiacinamidePhenylurea CompoundsProtein Kinase InhibitorsSorafenibVascular Endothelial Growth Factor AVEGFA protein, humanantiangiogenic therapybiomarkerhepatocellular carcinomaprognosisα-fetoprotein

Identifiers

PMID24122122
PMCPMC4209122
OpenAlexW1486451451

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.